Research Progress in Hepatocyte Growth Factor/Mesenchymal-epithelial Transition Factor Signaling Pathway:Effects and Mechanisms on Resistance to Targeted Therapy for Non-small Cell Lung Cancer / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 259-264, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-878729
ABSTRACT
Targeted therapy is an important therapeutic method for advanced non-small cell lung cancer with driver gene alteration.However,resistance to targeted therapy will inevitably happen in clinical practice,which has become a major issue demanding prompt solution.Studies have demonstrated that bypass resistance mediated by the activation of hepatocyte growth factor(HGF)/mesenchymal-epithelial transition factor(MET)signaling pathway is a common cause of resistance to targeted therapy.Presently,relevant studies have accumulated rich experience in the specific mechanisms.To be brief,HGF/MET is an important target for overcoming the resistance to targeted therapy and promises to be a leading biomarker for judging and observing the occurrence of resistance.This paper introduces the recent studies concerning the effects and mechanisms of HGF/MET signaling pathway on resistance to targeted therapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Transducción de Señal
/
Factor de Crecimiento de Hepatocito
/
Carcinoma de Pulmón de Células no Pequeñas
/
Proteínas Proto-Oncogénicas c-met
/
Transición Epitelial-Mesenquimal
/
Neoplasias Pulmonares
Límite:
Humanos
Idioma:
Chino
Revista:
Acta Academiae Medicinae Sinicae
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS